Puerarin Inhibits NLRP3-Caspase-1-GSDMD-Mediated Pyroptosis via P2X7 Receptor in Cardiomyocytes and Macrophages
Diabetic cardiomyopathy (DCM) is a critical complication of long-term chronic diabetes mellitus, and it is characterized by myocardial fibrosis and myocardial hypertrophy. Previous studies have shown that the pyroptosis pathway was significantly activated in DCM and may be related to the P2X7 receptor. However, the role of the P2X7 receptor in the development of DCM with pyroptosis is still unclear. In this study, we aimed to explore the mechanism of puerarin and whether the P2X7 receptor can be used as a new target for puerarin in the treatment of DCM. We adopted systematic pharmacology and bioinformatic approaches to identify the potential targets of puerarin for treating DCM. Additionally, we employed D-glucose-induced H9C2 rat cardiomyocytes and lipopolysaccharide-treated RAW264.7 mouse mononuclear macrophages as the in vitro model on DCM research, which is close to the pathological conditions. The mRNA expression of cytokines in H9C2 cells and RAW264.7 macrophages was detected. The protein expressions of NLRP3, N-GSDMD, cleaved-caspase-1, and the P2X7 receptor were investigated with Western blot analysis. Furthermore, molecular docking of puerarin and the P2X7 receptor was conducted based on CDOCKER. A total of 348 puerarin targets and 4556 diabetic cardiomyopathy targets were detected, of which 218 were cross targets. We demonstrated that puerarin is effective in enhancing cardiomyocyte viability and improving mitochondrial function. In addition, puerarin is efficacious in blocking NLRP3-Caspase-1-GSDMD-mediated pyroptosis in H9C2 cells and RAW264.7 cells, alleviating cellular inflammation. On the other hand, similar experimental results were obtained by intervention with the P2X7 receptor antagonist A740003, suggesting that the protective effects of puerarin are related to the P2X7 receptor. The molecular docking results indicated key binding activity between the P2X7 receptor and puerarin. These findings indicate that puerarin effectively regulated the pyroptosis signaling pathway during DCM, and this regulation was associated with the P2X7 receptor.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
Zur Gesamtaufnahme - volume:24 |
---|---|
Enthalten in: |
International journal of molecular sciences - 24(2023), 17 vom: 24. Aug. |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Sun, Shuchan [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 11.09.2023 Date Revised 11.09.2023 published: Electronic Citation Status MEDLINE |
---|
doi: |
10.3390/ijms241713169 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM361834721 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM361834721 | ||
003 | DE-627 | ||
005 | 20231226090001.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231226s2023 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.3390/ijms241713169 |2 doi | |
028 | 5 | 2 | |a pubmed24n1206.xml |
035 | |a (DE-627)NLM361834721 | ||
035 | |a (NLM)37685976 | ||
035 | |a (PII)13169 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Sun, Shuchan |e verfasserin |4 aut | |
245 | 1 | 0 | |a Puerarin Inhibits NLRP3-Caspase-1-GSDMD-Mediated Pyroptosis via P2X7 Receptor in Cardiomyocytes and Macrophages |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 11.09.2023 | ||
500 | |a Date Revised 11.09.2023 | ||
500 | |a published: Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Diabetic cardiomyopathy (DCM) is a critical complication of long-term chronic diabetes mellitus, and it is characterized by myocardial fibrosis and myocardial hypertrophy. Previous studies have shown that the pyroptosis pathway was significantly activated in DCM and may be related to the P2X7 receptor. However, the role of the P2X7 receptor in the development of DCM with pyroptosis is still unclear. In this study, we aimed to explore the mechanism of puerarin and whether the P2X7 receptor can be used as a new target for puerarin in the treatment of DCM. We adopted systematic pharmacology and bioinformatic approaches to identify the potential targets of puerarin for treating DCM. Additionally, we employed D-glucose-induced H9C2 rat cardiomyocytes and lipopolysaccharide-treated RAW264.7 mouse mononuclear macrophages as the in vitro model on DCM research, which is close to the pathological conditions. The mRNA expression of cytokines in H9C2 cells and RAW264.7 macrophages was detected. The protein expressions of NLRP3, N-GSDMD, cleaved-caspase-1, and the P2X7 receptor were investigated with Western blot analysis. Furthermore, molecular docking of puerarin and the P2X7 receptor was conducted based on CDOCKER. A total of 348 puerarin targets and 4556 diabetic cardiomyopathy targets were detected, of which 218 were cross targets. We demonstrated that puerarin is effective in enhancing cardiomyocyte viability and improving mitochondrial function. In addition, puerarin is efficacious in blocking NLRP3-Caspase-1-GSDMD-mediated pyroptosis in H9C2 cells and RAW264.7 cells, alleviating cellular inflammation. On the other hand, similar experimental results were obtained by intervention with the P2X7 receptor antagonist A740003, suggesting that the protective effects of puerarin are related to the P2X7 receptor. The molecular docking results indicated key binding activity between the P2X7 receptor and puerarin. These findings indicate that puerarin effectively regulated the pyroptosis signaling pathway during DCM, and this regulation was associated with the P2X7 receptor | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a H9C2 cell | |
650 | 4 | |a P2X7 receptor | |
650 | 4 | |a RAW264.7 macrophages | |
650 | 4 | |a diabetic cardiomyopathy | |
650 | 4 | |a puerarin | |
650 | 4 | |a pyroptosis | |
650 | 7 | |a puerarin |2 NLM | |
650 | 7 | |a Z9W8997416 |2 NLM | |
650 | 7 | |a NLR Family, Pyrin Domain-Containing 3 Protein |2 NLM | |
650 | 7 | |a Receptors, Purinergic P2X7 |2 NLM | |
650 | 7 | |a Caspase 1 |2 NLM | |
650 | 7 | |a EC 3.4.22.36 |2 NLM | |
700 | 1 | |a Gong, Difei |e verfasserin |4 aut | |
700 | 1 | |a Liu, Ruiqi |e verfasserin |4 aut | |
700 | 1 | |a Wang, Ranran |e verfasserin |4 aut | |
700 | 1 | |a Chen, Di |e verfasserin |4 aut | |
700 | 1 | |a Yuan, Tianyi |e verfasserin |4 aut | |
700 | 1 | |a Wang, Shoubao |e verfasserin |4 aut | |
700 | 1 | |a Xing, Cheng |e verfasserin |4 aut | |
700 | 1 | |a Lv, Yang |e verfasserin |4 aut | |
700 | 1 | |a Du, Guanhua |e verfasserin |4 aut | |
700 | 1 | |a Fang, Lianhua |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t International journal of molecular sciences |d 2008 |g 24(2023), 17 vom: 24. Aug. |w (DE-627)NLM185552161 |x 1422-0067 |7 nnns |
773 | 1 | 8 | |g volume:24 |g year:2023 |g number:17 |g day:24 |g month:08 |
856 | 4 | 0 | |u http://dx.doi.org/10.3390/ijms241713169 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 24 |j 2023 |e 17 |b 24 |c 08 |